1. Home
  2. NLSP

NLSP

NLS Pharmaceutics Ltd.

Logo NLS Pharmaceutics Ltd.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 11:55am EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Founded: 2015 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 5.5M IPO Year: 2021
Target Price: N/A AVG Volume (30 days): 571.1K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.50 EPS Growth: N/A
52 Week Low/High: $0.13 - $1.58 Next Earning Date: 05-03-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: